Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial
- PMID: 9024712
Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial
Abstract
Background: Previous Phase II studies using the combination of mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast carcinoma have shown this regimen to be active and well tolerated. In this randomized Phase II study, the authors compared the NFL regimen with a standard CMF regimen in the first-line therapy of patients with metastatic breast carcinoma.
Methods: One hundred twenty-eight women receiving their first chemotherapy for metastatic breast carcinoma were entered into this randomized study. Sixty-four patients were treated with NFL: mitoxantrone 12 mg/m2 IV on Day 1; leucovorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding administration of 5-fluorouracil; and 5-fluorouracil 350 mg/m2 IV bolus on Days 1, 2, and 3. Sixty-four patients received CMF: cyclophosphamide 600 mg/m2 IV on Day 1; methotrexate 40 mg/m2 IV on Day 1; and 5-fluorouracil 600 mg/m2 IV on Day 1. Both regimens were repeated at 21-day intervals; responding patients received at least 8 courses.
Results: Patients treated with NFL had a higher response rate than patients treated with the CMF regimen (45% vs. 26%, respectively; P = 0.021). Median duration of response was 9 months with NFL and 6 months with CMF (P = 0.10); 11 patients had long responses (>12 months) with NFL versus 4 patients with CMF (P = 0.06). Median survival was similar for both groups. Both regimens were well tolerated, with infrequent Grade 3 or 4 toxicities.
Conclusions: NFL is an active, well-tolerated regimen for the treatment of metastatic breast carcinoma; it produced a higher response rate than the CMF regimen used in this study. Although more intense CMF regimens or regimens containing doxorubicin would likely increase the response rate, they would almost certainly do so with the consequence of greater toxicity as compared with NFL. NFL is an excellent initial palliative treatment option for elderly patients or patients who have exhibited poor tolerance for other chemotherapy regimens.
Similar articles
-
Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-61-S17-64. Semin Oncol. 1997. PMID: 9374096 Clinical Trial.
-
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.Cancer. 1998 Mar 1;82(5):878-85. Cancer. 1998. PMID: 9486577 Clinical Trial.
-
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.Cancer. 2002 Jul 15;95(2):228-35. doi: 10.1002/cncr.10678. Cancer. 2002. PMID: 12124820 Clinical Trial.
-
[Concomitant association of radiotherapy and chemotherapy in inflammatory breast cancer. Initial results of phase II trial].Bull Cancer. 1991;78(5):445-52. Bull Cancer. 1991. PMID: 1878606 Review. French.
-
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.Ann Oncol. 2003 Jun;14(6):833-42. doi: 10.1093/annonc/mdg260. Ann Oncol. 2003. PMID: 12796019 Review.
Cited by
-
Antitumour antibiotic containing regimens for metastatic breast cancer.Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD003367. doi: 10.1002/14651858.CD003367.pub2. Cochrane Database Syst Rev. 2004. PMID: 15495049 Free PMC article.
-
Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.J Neurooncol. 2004 Jul;68(3):225-32. doi: 10.1023/b:neon.0000033381.96370.6b. J Neurooncol. 2004. PMID: 15332325
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Medical